Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 14/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834857 | 0.83 | ITGB3 (0.46) | LMNAITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL5175196 | 0.83 | ITGB3 (0.43) | LMNAITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL4899787 | 0.82 | ITGB3 (0.62) | ITGB3ITGA2BITGAVPPARG | |
| SCHEMBL4894047 | 0.81 | LMNA (0.43) | LMNAITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL4832623 | 0.76 | ITGB3 (0.46) | LMNAITGB3ITGA2BITGAV | |
| SCHEMBL5174469 | 0.75 | ITGB3 (0.42) | LMNAITGB3ITGA2BITGAVPPARG | |
| SCHEMBL14253148 | 0.74 | ACACB (0.46) | — | |
| SCHEMBL5177244 | 0.73 | ITGB3 (0.44) | ITGB3ITGA2BITGAVKLKB1 | |
| SCHEMBL4832543 | 0.72 | ITGB3 (0.55) | LMNAITGB3ITGA2BITGAV | |
| SCHEMBL4835350 | 0.71 | ITGB3 (0.60) | LMNAITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. | 2008-01-24 | — | — | US | disclosed |
| US-6399620-B1 | (2S)-2-(1-ADAMANTYL-METHYLOXYCARBONYLAMINO)-3-(4-(3-GUANIDINO -CARBONYL-PROPYLOXY)PHENYL)PROPIONIC ACID; ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; CARDIOVASCULAR DISORDERS | AVENTIS PHARMA S.A. (DE) | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | ADGRF1, ADGRE5, CALCR | LMNA 498/4885ITGB3 536/4885ITGA2B 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.